broad_id
string | depmap_id
string | ccle_name
string | screen_id
string | upper_limit
int64 | lower_limit
float64 | slope
float64 | r2
float64 | auc
float64 | ec50
float64 | ic50
float64 | name
string | moa
string | target
string | disease.area
string | indication
string | smiles
string | phase
string | passed_str_profiling
bool | row_name
string |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BRD-K03390685-001-01-7 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.991057 | -0.178123 | -0.072552 | 0.992532 | 1,114.014691 | null | cobimetinib | MEK inhibitor | null | oncology | melanoma | OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1 | Launched | true | ACH-000984 |
BRD-K03406345-001-21-1 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.99815 | -0.273218 | -0.058668 | 0.9992 | 0.024994 | null | azacitidine | DNA methyltransferase inhibitor | DNMT1, DNMT3A | hematologic malignancy, hematology | myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL) | Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000984 |
BRD-K03449891-001-08-6 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 2.58502 | 2.194831 | 0.375153 | 1 | 2.957696 | null | foretinib | VEGFR inhibitor | FLT1, FLT4, KDR, MET | null | null | COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1 | Phase 2 | true | ACH-000984 |
BRD-K06814349-304-02-7 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.972913 | 0.044966 | -0.002419 | 0.986623 | 0.135108 | null | fosbretabulin | tubulin polymerization inhibitor, VE-cadherin antagonist | CDH5 | null | null | COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O | Phase 3 | true | ACH-000984 |
BRD-K08109215-001-06-4 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.603226 | 0.172507 | 0.063242 | 0.748293 | 0.002675 | null | I-BET-762 | bromodomain inhibitor | BRD2, BRD3, BRD4 | null | null | CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 | Phase 2 | true | ACH-000984 |
BRD-K08542803-001-02-3 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | -0.106426 | 0.538257 | 0.603509 | 0.615049 | 0.446104 | 0.311694 | gambogic-acid | caspase activator | BCL2 | null | null | CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C | Phase 2 | true | ACH-000984 |
BRD-K08547377-001-04-4 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.091422 | 6.775067 | 0.406717 | 0.75715 | 0.747274 | 0.769865 | irinotecan | topoisomerase inhibitor | TOP1, TOP1MT | oncology | colorectal cancer | CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12 | Launched | true | ACH-000984 |
BRD-K08703257-001-13-9 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.958168 | -0.145469 | -0.057021 | 0.973161 | 5.0191 | null | 3-amino-benzamide | PARP inhibitor | PARP1 | null | null | NC(=O)c1cccc(N)c1, NC(=O)c1cccc(N)c1 | Phase 2 | true | ACH-000984 |
BRD-K09951645-001-11-8 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 1.327393 | 0.258919 | 0.072299 | 1 | 0.805478 | null | dabrafenib | RAF inhibitor | BRAF, LIMK1, NEK11, RAF1, SIK1 | oncology | melanoma | CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F | Launched | true | ACH-000984 |
BRD-K11267252-001-05-1 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.951299 | 0.197218 | -0.014181 | 0.969079 | 0.003845 | null | alectinib | ALK tyrosine kinase receptor inhibitor | ALK, MET | oncology | non-small cell lung cancer (NSCLC) | CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1, CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1 | Launched | true | ACH-000984 |
BRD-K11630072-001-13-2 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 1.154581 | -0.254665 | -0.034927 | 1 | 0.078856 | null | carmofur | thymidylate synthase inhibitor | TYMS | oncology | breast cancer, colorectal cancer | CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O | Launched | true | ACH-000984 |
BRD-K12184916-001-19-6 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 1.324966 | 0.506271 | 0.016725 | 1 | 0.252069 | null | NVP-BEZ235 | mTOR inhibitor, PI3K inhibitor | ATR, MTOR, PIK3CA, PIK3CD, PIK3CG | null | null | Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1, Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1 | Phase 2 | true | ACH-000984 |
BRD-K12343256-001-14-7 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 1.776858 | 0.22115 | 0.129401 | 1 | 0.398941 | null | trametinib | MEK inhibitor | MAP2K1, MAP2K2 | oncology | melanoma | CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O | Launched | true | ACH-000984 |
BRD-K13049116-001-04-0 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 2.05318 | 5.265636 | 0.686206 | 1 | 0.977763 | null | BMS-754807 | IGF-1 inhibitor | AKT1, IGF1R | null | null | C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1 | Phase 2 | true | ACH-000984 |
BRD-K13390322-001-06-3 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.13736 | 3.937848 | 0.850784 | 0.696649 | 0.329529 | 0.357532 | AT-7519 | CDK inhibitor | CDK1, CDK2, CDK4, CDK5, CDK6, CDK9 | null | null | Clc1cccc(Cl)c1C(=O)Nc1c[nH]nc1C(=O)NC1CCNCC1 | Phase 2 | true | ACH-000984 |
BRD-K13514097-001-04-6 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 2.225689 | 0.110824 | 0.103571 | 1 | 24.486549 | null | everolimus | mTOR inhibitor | MTOR | oncology, neurology/psychiatry, genetics, urology | breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma | CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO | Launched | true | ACH-000984 |
BRD-K13662825-001-07-5 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.167805 | 0.96855 | 0.637365 | 0.515616 | 0.008681 | 0.013241 | dinaciclib | CDK inhibitor | CDK1, CDK2, CDK5, CDK9 | null | null | CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO | Phase 3 | true | ACH-000984 |
BRD-K14109347-001-03-4 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.109223 | 6.608674 | 0.776021 | 0.848965 | 1.929233 | 2.002558 | LY2603618 | CHK inhibitor | CHEK1 | null | null | Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1, Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1 | Phase 2 | true | ACH-000984 |
BRD-K15179879-001-03-2 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.094549 | 0.400461 | 0.651327 | 0.455354 | 0.020691 | 0.034922 | carfilzomib | proteasome inhibitor | PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9 | hematologic malignancy | multiple myeloma | CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1 | Launched | true | ACH-000984 |
BRD-K15600710-066-05-8 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.329775 | 7.337829 | 0.561279 | 0.766385 | 0.333407 | 0.386141 | obatoclax | BCL inhibitor | BCL2 | null | null | COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1, COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 | Phase 3 | true | ACH-000984 |
BRD-K16730910-001-10-7 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 1.020819 | -0.242137 | -0.003395 | 1 | 37.334313 | null | regorafenib | FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK | oncology | colorectal cancer, gastrointestinal stromal tumors (GIST) | CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1 | Launched | true | ACH-000984 |
BRD-K17555800-003-02-3 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 1.188543 | 0.460403 | -0.052746 | 1 | 0.392234 | null | talmapimod | p38 MAPK inhibitor | MAPK11, MAPK14 | null | null | C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C | Phase 2 | true | ACH-000984 |
BRD-K17610631-001-03-3 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.782736 | 0.436069 | 0.008306 | 0.870493 | 0.022824 | null | indisulam | CDK inhibitor | CA1, CA12, CA14, CA2, CA6, CA7, CA9 | null | null | NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12 | Phase 2 | true | ACH-000984 |
BRD-K17743125-001-08-4 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.247296 | 4.506179 | 0.677876 | 0.754461 | 0.421829 | 0.49079 | belinostat | HDAC inhibitor | HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9 | hematologic malignancy | peripheral T-cell lymphoma (PTCL) | ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1 | Launched | true | ACH-000984 |
BRD-K17894950-001-14-3 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 1.313081 | 0.101798 | -0.048779 | 1 | 0.000541 | null | indirubin | CDK inhibitor, glycogen synthase kinase inhibitor | CDK1, CDK5, GSK3A | null | null | O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O | Phase 2/Phase 3 | true | ACH-000984 |
BRD-K18961567-001-01-1 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.754664 | 1.506436 | 0.058885 | 0.91405 | 0.335092 | null | LY2801653 | MET inhibitor | MET | null | null | Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1 | Phase 2 | true | ACH-000984 |
BRD-K19540840-001-09-4 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 1.110415 | -0.275163 | -0.130752 | 1 | 0.031759 | null | saracatinib | src inhibitor | ABL1, LCK, SRC, YES1 | null | null | CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1 | Phase 2/Phase 3 | true | ACH-000984 |
BRD-K19687926-001-04-1 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.950636 | -0.628193 | -0.1519 | 0.985182 | 0.008697 | null | lapatinib | EGFR inhibitor | EGFR, ERBB2 | oncology | breast cancer | CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1 | Launched | true | ACH-000984 |
BRD-K19796430-001-05-6 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 1.181118 | 0.180136 | -0.054503 | 1 | 0.006937 | null | sonidegib | smoothened receptor antagonist | SMO | oncology | basal cell carcinoma (BCC) | C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1, C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1 | Launched | true | ACH-000984 |
BRD-K22064724-001-01-8 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 1.015547 | -3.493567 | -0.001651 | 1 | 0.010251 | null | napabucasin | STAT inhibitor | STAT3 | null | null | CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O, CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O | Phase 3 | true | ACH-000984 |
BRD-K22822991-001-02-3 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.694518 | -0.108299 | -0.150611 | 0.857938 | 0.020805 | null | odanacatib | cathepsin inhibitor | CTSK | null | null | CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N | Phase 3 | true | ACH-000984 |
BRD-K23228615-001-02-8 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 1.429508 | 3.681286 | 0.448165 | 1 | 0.11722 | null | GDC-0980 | mTOR inhibitor, PI3K inhibitor | FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK | null | null | C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1 | Phase 2 | true | ACH-000984 |
BRD-K26026438-001-01-0 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.812088 | 10.455828 | 0.093653 | 0.879222 | 0.019547 | null | tucatinib | EGFR inhibitor | ERBB2 | null | null | Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1 | Phase 2 | true | ACH-000984 |
BRD-K26657438-001-15-2 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.927573 | 3.500867 | 0.099377 | 0.958133 | 0.036618 | null | imiquimod | interferon inducer, toll-like receptor agonist | TLR7, TLR8 | dermatology, infectious disease, oncology | actinic keratosis (AK), genital warts, basal cell carcinoma (BCC) | CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12 | Launched | true | ACH-000984 |
BRD-K28822270-001-03-7 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.175096 | 2.063237 | 0.721859 | 0.647804 | 0.166126 | 0.204727 | resminostat | HDAC inhibitor | HDAC1, HDAC3, HDAC6, HDAC8 | null | null | CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO | Phase 2 | true | ACH-000984 |
BRD-K29905972-001-06-3 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.874255 | -6.70354 | -0.005568 | 0.883943 | 4.739213 | null | axitinib | PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1, FLT1, FLT4, KDR, PLK4 | oncology | renal cell carcinoma (RCC) | CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1 | Launched | true | ACH-000984 |
BRD-K30577245-001-05-0 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.230883 | 0.120046 | -0.089386 | 0.664171 | 0.04325 | null | docetaxel | tubulin polymerization inhibitor | BCL2, MAP2, MAP4, MAPT, NR1I2, TUBB, TUBB1 | oncology | breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC) | CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C | Launched | true | ACH-000984 |
BRD-K31698212-001-02-9 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 1.544935 | 0.581804 | 0.06575 | 1 | 9.43108 | null | icotinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1 | Launched | true | ACH-000984 |
BRD-K31928526-001-02-1 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 2.048278 | 1.005012 | 0.36951 | 1 | 2.173538 | null | barasertib | Aurora kinase inhibitor | AURKA, AURKB | null | null | CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(O)(O)=O | Phase 2/Phase 3 | true | ACH-000984 |
BRD-K33379087-001-07-5 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.871064 | 0.278682 | 0.00891 | 0.889082 | 0.000054 | null | tivantinib | tyrosine kinase inhibitor | MET | null | null | O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23 | Phase 3 | true | ACH-000984 |
BRD-K33610132-001-02-9 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.730013 | 0.085555 | 0.010411 | 0.85072 | 0.006292 | null | rociletinib | EGFR inhibitor | EGFR | null | null | COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O | Phase 3 | true | ACH-000984 |
BRD-K33622447-066-01-9 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.346263 | 10.703646 | 0.688896 | 0.861638 | 1.282253 | 1.431619 | abemaciclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1 | Launched | true | ACH-000984 |
BRD-K35520305-001-16-9 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.994925 | -0.274851 | -0.035655 | 0.997073 | 0.282811 | null | dacarbazine | DNA alkylating agent | PGD, POLA2 | oncology, hematologic malignancy | melanoma, Hodgkin's lymphoma | CN(C)\N=N\c1[nH]cnc1C(N)=O, CN(C)\N=N\c1[nH]cnc1C(N)=O | Launched | true | ACH-000984 |
BRD-K36627727-001-05-4 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.750003 | 0.475218 | -0.024501 | 0.869593 | 0.060428 | null | tamibarotene | retinoid receptor agonist | RARA, RARB | hematologic malignancy | acute promyelocytic leukemia (APL) | CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12 | Launched | true | ACH-000984 |
BRD-K36788280-001-01-2 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.963145 | -0.094093 | -0.011662 | 0.983941 | 0.004774 | null | ribociclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1 | Launched | true | ACH-000984 |
BRD-K37379014-001-02-0 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 2.068467 | 1.627974 | 0.604567 | 1 | 0.008112 | null | filanesib | kinesin inhibitor, kinesin-like spindle protein inhibitor | KIF11 | null | null | CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F | Phase 3 | true | ACH-000984 |
BRD-K38332599-001-01-3 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.712282 | 4.977197 | 0.313661 | 0.920154 | 0.676647 | null | uprosertib | AKT inhibitor | AKT1, AKT2, AKT3 | null | null | Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1 | Phase 2 | true | ACH-000984 |
BRD-K38527262-300-01-0 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.160076 | 6.858334 | 0.503019 | 0.867974 | 2.002392 | 2.118287 | atiprimod | JAK inhibitor, STAT inhibitor | JAK2, STAT3 | null | null | CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1 | Phase 2 | true | ACH-000984 |
BRD-K38852836-001-02-1 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.216452 | 11.387084 | 0.721246 | 0.608781 | 0.019693 | 0.020699 | ganetespib | HSP inhibitor | HSP90AA1 | null | null | CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O | Phase 3 | true | ACH-000984 |
BRD-K39974922-001-04-3 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.76841 | -0.132553 | -0.060713 | 0.828649 | 266.226428 | null | lenvatinib | FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | FLT4, KDR | oncology | thyroid cancer | COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O | Launched | true | ACH-000984 |
BRD-K41859756-001-06-8 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.24007 | 4.360897 | 0.816755 | 0.56173 | 0.009291 | 0.010795 | NVP-AUY922 | HSP inhibitor | HSP90AA1, HSP90AB1 | null | null | CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O | Phase 2 | true | ACH-000984 |
BRD-K42495768-001-01-7 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.908238 | -0.055206 | -0.057876 | 0.943747 | 341.250681 | null | tasisulam | apoptosis stimulant | null | null | null | Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1 | Phase 3 | true | ACH-000984 |
BRD-K42805893-001-04-9 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | -0.804238 | 1.360773 | 0.207269 | 0.950424 | 18.360249 | 9.075822 | osimertinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12 | Launched | true | ACH-000984 |
BRD-K42828737-001-03-3 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 1.46069 | 0.185825 | -0.02941 | 1 | 123.250633 | null | sunitinib | FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET | oncology | gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET) | CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C | Launched | true | ACH-000984 |
BRD-K42898655-001-01-8 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 1.228019 | 0.408017 | 0.002467 | 1 | 0.016666 | null | temsirolimus | mTOR inhibitor | MTOR | oncology | renal cell carcinoma (RCC) | CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1OC(=O)C(C)(CO)CO | Launched | true | ACH-000984 |
BRD-K43389675-001-02-1 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.164953 | 3.688432 | 0.72657 | 0.668363 | 0.21191 | 0.236205 | daunorubicin | RNA synthesis inhibitor, topoisomerase inhibitor | TOP2A, TOP2B | hematologic malignancy | acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) | COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O | Launched | true | ACH-000984 |
BRD-K44227013-001-06-4 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.949927 | -0.023942 | -0.002038 | 0.974101 | 1.39248 | null | ponatinib | Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor | ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK | hematologic malignancy | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) | CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1 | Launched | true | ACH-000984 |
BRD-K44827188-001-06-0 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.748436 | -0.219715 | 0.009601 | 0.899094 | 0.01066 | null | vismodegib | hedgehog pathway inhibitor, smoothened receptor antagonist | SMO | oncology | basal cell carcinoma (BCC) | Clc1cc(ccc1C(=O)Nc1ccc(Cl)c(c1)-c1ccccn1)S(C)(=O)=O | Launched | true | ACH-000984 |
BRD-K46386702-001-02-1 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.954476 | -1.080793 | 0.017812 | 0.964504 | 1.298555 | null | ARRY-334543 | EGFR inhibitor | ERBB2 | null | null | C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1 | Phase 2 | true | ACH-000984 |
BRD-K49328571-001-15-0 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.611409 | 0.273865 | -0.105563 | 0.773972 | 0.019768 | null | dasatinib | Bcr-Abl kinase inhibitor, ephrin inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor, tyrosine kinase inhibitor | ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1 | hematologic malignancy | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) | Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1, Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1 | Launched | true | ACH-000984 |
BRD-K49350383-001-14-5 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 1.290866 | -0.444554 | -0.048774 | 1 | 0.015496 | null | thioguanine | purine antagonist | IMPDH1, IMPDH2 | hematologic malignancy | acute myeloid leukemia (AML) | Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1 | Launched | true | ACH-000984 |
BRD-K50010139-001-01-5 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 1.39623 | 0.095995 | -0.067343 | 1 | 0.014776 | null | poziotinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | null | null | COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C | Phase 2 | true | ACH-000984 |
BRD-K50168500-001-07-9 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | -3.933342 | 1.832 | -0.029649 | 0.97666 | 37.74238 | null | canertinib | EGFR inhibitor | AKT1, EGFR, ERBB2, ERBB4 | null | null | Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl | Phase 3 | true | ACH-000984 |
BRD-K51313569-001-07-8 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.225575 | 8.366246 | 0.314712 | 0.9782 | 7.707672 | 8.280666 | palbociclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O | Launched | true | ACH-000984 |
BRD-K51791723-003-01-7 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.156865 | 0.580144 | 0.548312 | 0.692111 | 0.348448 | 0.666758 | P276-00 | CDK inhibitor | CDK1, CDK4, CDK9 | null | null | CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl | Phase 2 | true | ACH-000984 |
BRD-K51967704-001-03-6 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.321382 | 9.270548 | 0.561334 | 0.754845 | 0.300209 | 0.335464 | BIIB021 | HSP inhibitor | HSP90AA1 | null | null | COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C | Phase 2 | true | ACH-000984 |
BRD-K52313696-001-12-3 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.915522 | 0.226151 | 0.006676 | 0.948401 | 0.008782 | null | tacedinaline | HDAC inhibitor | HDAC1 | null | null | CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N | Phase 3 | true | ACH-000984 |
BRD-K53414658-001-08-2 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.757807 | 0.035555 | -0.124917 | 0.865224 | 0.00013 | null | tivozanib | VEGFR inhibitor | FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB | null | null | COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC | Phase 3 | true | ACH-000984 |
BRD-K53972329-001-07-0 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.593179 | 0.065473 | -0.008012 | 0.830974 | 14.989228 | null | ruxolitinib | JAK inhibitor | JAK1, JAK2, JAK3, TYK2 | hematologic malignancy, hematology | myelofibrosis, polycythemia vera | N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12 | Launched | true | ACH-000984 |
BRD-K54256913-001-08-7 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.075718 | 1.056675 | 0.85116 | 0.640123 | 0.232194 | 0.271233 | MK-1775 | WEE1 kinase inhibitor | WEE1 | null | null | CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1 | Phase 2 | true | ACH-000984 |
BRD-K54997624-001-06-0 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 1.009281 | -0.376467 | -0.269399 | 1 | 0.562741 | null | alpelisib | PI3K inhibitor | PIK3CA, PIK3CB, PIK3CD, PIK3CG | null | null | Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F | Phase 3 | true | ACH-000984 |
BRD-K55187425-236-05-2 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 1.220309 | 0.040404 | -0.000637 | 1 | 14,315,630,264,096,034 | null | rigosertib | cell cycle inhibitor, PLK inhibitor | PLK1 | null | null | COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1 | Phase 3 | true | ACH-000984 |
BRD-K56343971-001-14-8 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.857152 | -1.295904 | -0.050978 | 0.940872 | 0.033748 | null | vemurafenib | RAF inhibitor | BRAF, RAF1 | oncology | melanoma | CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F | Launched | true | ACH-000984 |
BRD-K56981171-001-02-8 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.783448 | -5.203917 | 0.147918 | 0.860787 | 0.312453 | null | brigatinib | ALK tyrosine kinase receptor inhibitor, EGFR inhibitor | ALK, EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1 | Launched | true | ACH-000984 |
BRD-K57080016-001-15-9 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 1.469087 | 2.111007 | 0.495196 | 1 | 0.480278 | null | selumetinib | MEK inhibitor | MAP2K1 | null | null | Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO | Phase 3 | true | ACH-000984 |
BRD-K57169635-001-04-5 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.054392 | 3.270877 | 0.449944 | 0.949519 | 6.33793 | 6.564945 | dacomitinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | null | null | COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1 | Phase 3 | true | ACH-000984 |
BRD-K58435339-001-03-0 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.223667 | 0.802557 | 0.654519 | 0.639223 | 0.111589 | 0.233624 | AT13387 | HSP antagonist | HSP90AA1 | null | null | CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O | Phase 2 | true | ACH-000984 |
BRD-K58529924-001-01-5 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 1.2465 | -0.415299 | -0.005947 | 1 | 0.007397 | null | ONC201 | AKT inhibitor, MAP kinase inhibitor | TNFSF10 | null | null | Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O | Phase 2 | true | ACH-000984 |
BRD-K58550667-001-08-7 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.121293 | 4.830142 | 0.922408 | 0.602764 | 0.00777 | 0.00823 | FK-866 | niacinamide phosphoribosyltransferase inhibitor | NAMPT | null | null | O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1 | Phase 2 | true | ACH-000984 |
BRD-K59369769-001-22-9 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 1.041272 | -0.428811 | -0.245128 | 1 | 0.065097 | null | tozasertib | Aurora kinase inhibitor, Bcr-Abl kinase inhibitor, FLT3 inhibitor, JAK inhibitor | AURKA, AURKB, AURKC, LCK | null | null | CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1 | Phase 2 | true | ACH-000984 |
BRD-K60866521-001-07-1 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.606336 | -0.362484 | -0.08246 | 0.80392 | 0.07608 | null | idelalisib | PI3K inhibitor | PIK3CA, PIK3CB, PIK3CD, PIK3CG | hematologic malignancy | chronic lymphocytic leukemia (CLL) | CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1 | Launched | true | ACH-000984 |
BRD-K60997853-001-02-3 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.058734 | 1.6554 | 0.658525 | 0.847942 | 2.185168 | 2.356501 | PHA-848125 | CDK inhibitor, growth factor receptor inhibitor | CDK2, CDK4, CDK7, NTRK1 | null | null | CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21 | Phase 2 | true | ACH-000984 |
BRD-K61192372-001-08-9 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.872373 | -4.576992 | 0.087875 | 0.883171 | 4.422394 | null | capecitabine | DNA synthesis inhibitor, thymidylate synthase inhibitor | TYMS | oncology | breast cancer, colorectal cancer | CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O | Launched | true | ACH-000984 |
BRD-K62008436-001-23-9 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.32467 | 0.522341 | 0.262002 | 0.556372 | 0.000788 | 0.005862 | paclitaxel | tubulin polymerization inhibitor | BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBB, TUBB1 | oncology | ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC) | CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 | Launched | true | ACH-000984 |
BRD-K62196610-001-01-6 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.95967 | -0.052761 | -0.00885 | 0.979477 | 0.153591 | null | AVN-944 | inosine monophosphate dehydrogenase inhibitor | IMPDH1, IMPDH2 | null | null | CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1 | Phase 2 | true | ACH-000984 |
BRD-K62200014-003-10-5 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.75713 | 0.152233 | -0.113746 | 0.849593 | 0.002775 | null | anagrelide | phosphodiesterase inhibitor | PDE3A | hematology, hematologic malignancy | thrombocythemia, myeloproliferative neoplasms | Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl | Launched | true | ACH-000984 |
BRD-K62391742-001-09-7 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.913838 | -1.798532 | 0.027525 | 0.942765 | 0.385225 | null | venetoclax | BCL inhibitor | BCL2 | hematologic malignancy | chronic lymphocytic leukemia (CLL) | CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 | Launched | true | ACH-000984 |
BRD-K62627508-001-01-5 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 2.930017 | 1.617143 | 0.43954 | 1 | 4.96375 | null | idasanutlin | MDM inhibitor | MDM2, TP53 | null | null | COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O | Phase 3 | true | ACH-000984 |
BRD-K63504947-001-14-7 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 1.53109 | 0.190479 | 0.15517 | 1 | 0.703003 | null | semaxanib | VEGFR inhibitor | FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET | null | null | Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1 | Phase 3 | true | ACH-000984 |
BRD-K63712959-001-01-8 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.891073 | -4.426759 | 0.093741 | 0.945507 | 0.078311 | null | temoporfin | radical formation stimulant | null | oncology | head and neck squamous cell carcinoma (HNSCC) | Oc1cccc(c1)-c1c2CCc(n2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc(n2)c(-c2cccc(O)c2)c2ccc1[nH]2 | Launched | true | ACH-000984 |
BRD-K64052750-001-22-5 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 1.359549 | 0.083541 | 0.053466 | 1 | 1.220522 | null | gefitinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1 | Launched | true | ACH-000984 |
BRD-K64881305-001-03-7 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 4.080089 | 0.382848 | 0.313679 | 1 | 1.708491 | null | ispinesib | kinesin inhibitor | KIF11 | null | null | CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1 | Phase 2 | true | ACH-000984 |
BRD-K66175015-001-12-4 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 1.212222 | -0.117111 | -0.00071 | 1 | 0.010208 | null | afatinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | oncology | non-small cell lung cancer (NSCLC) | CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1 | Launched | true | ACH-000984 |
BRD-K67844266-003-01-9 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.477812 | 1.765764 | 0.486539 | 0.680457 | 0.026339 | 0.153733 | pevonedistat | nedd activating enzyme inhibitor | NAE1, UBA3 | null | null | NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12 | Phase 2 | true | ACH-000984 |
BRD-K69694239-001-02-2 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.299901 | 3.870777 | 0.798693 | 0.794321 | 0.577824 | 0.732071 | bardoxolone-methyl | nuclear factor erythroid derived, like (NRF2) activator | PPARG, STAT3 | null | null | COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 | Phase 3 | true | ACH-000984 |
BRD-K69776681-001-03-8 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.4003 | 0.408462 | 0.112979 | 0.692485 | 0.066308 | 3.43546 | volasertib | PLK inhibitor | PLK1 | null | null | CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O | Phase 3 | true | ACH-000984 |
BRD-K70301465-001-05-9 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 1.320337 | 1.866901 | -0.037602 | 1 | 0.051142 | null | ibrutinib | Bruton's tyrosine kinase (BTK) inhibitor | BLK, BMX, BTK | hematologic malignancy | chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM) | Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C | Launched | true | ACH-000984 |
BRD-K73838513-003-05-5 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | -0.517496 | 3.226458 | 0.583698 | 0.970593 | 10.576786 | 8.486301 | cinacalcet | calcium channel activator | CASR | endocrinology, nephrology, oncology | hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia | C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12 | Launched | true | ACH-000984 |
BRD-K74514084-003-09-2 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.772531 | -0.368991 | -0.03526 | 0.940094 | 0.002523 | null | pazopanib | KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3 | oncology | renal cell carcinoma (RCC), soft tissue sarcoma (STS) | CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1 | Launched | true | ACH-000984 |
BRD-K75009076-001-02-1 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.065436 | 0.925812 | 0.710412 | 0.701135 | 0.476912 | 0.554926 | SCH-900776 | CHK inhibitor | CDK2, CHEK1 | null | null | Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1, Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1 | Phase 2 | true | ACH-000984 |
Subsets and Splits
No saved queries yet
Save your SQL queries to embed, download, and access them later. Queries will appear here once saved.